Anti-angiogenesis boosts chemo-immunotherapy in patients with EGFR mutations or baseline liver metastases: insights from IMpower150 study
Sign Up to like & getrecommendations! Published in 2019 at "Translational cancer research"
DOI: 10.21037/tcr.2019.06.21
Abstract: The first-line treatment scenario of advanced non-small cell lung cancer (NSCLC) has been substantially revolutionized in the very last years, since immunotherapy has become a cornerstone. read more here.
Keywords: anti angiogenesis; immunotherapy patients; chemo immunotherapy; boosts chemo ... See more keywords